Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
CME Group arrives at its October 21 Q3 earnings with the Street more constructive than a week ago and the stock up nearly 3% on the week to $278.03, yet still sitting below a mean price target that continues to climb.
The analyst story has accelerated since the last note filed October 7. Wells Fargo raised its target to $315 from $301 this morning, maintaining Overweight. Morgan Stanley lifted to $337 from $330 last Friday, also keeping Overweight. Both moves came within the past five days and both shift in the same direction. The mean target now stands at $292.88, implying roughly 5% upside from current levels. The directional split on the Street remains intact: Morgan Stanley and Wells Fargo anchor the bull camp well above $300, while JP Morgan holds Underweight at $250 and Barclays sits at Equal-Weight with a $281 target. The bull case rests on Market Data revenue growing 14.5% in the most recent quarter and a free cash flow track record that has funded 14-plus consecutive years of dividend growth. Bears focus on a rate-cutting cycle that crimps interest rate futures volumes and competitive pressure from FMX limiting near-term margin expansion. Factor scores add texture: the analyst recommendation divergence ranks in the 96th percentile across the ORTEX universe, meaning the gap between the most bullish and most cautious views on CME is unusually wide. EPS surprise history scores in the 61st percentile, broadly in line. Value looks stretched, with EV/EBIT in the 23rd percentile.
Positioning in the lending market tells a quiet story. Short interest is low at 1.5% of free float and has been drifting lower, down about 1.6% over the week and trimmed a further 0.7% on Tuesday. The borrow pool is enormous: availability is effectively uncapped, with roughly 274 million shares available against just 5.4 million shorted, so there is no meaningful squeeze dynamic and no cost pressure from borrow scarcity. Cost to borrow has ticked up sharply in percentage terms, jumping 46% over the week to 0.54%, but the absolute level remains trivial. This is not a borrow-constrained name. Options positioning is mild. The put/call ratio is 1.16, only fractionally above its 20-day average of 1.15 and well within one standard deviation of normal. There is no unusual hedging cluster visible ahead of the print.
The one genuine curiosity this week is the insider register. The September 16 cluster of tax-withholding transactions across eight executives, CFO Lynne Fitzpatrick, the CIO, the COO, and five senior MDs, was compensation mechanics rather than conviction selling; withholding is how executives cover a tax bill at vesting, not a discretionary exit. The only open-market trade in the past 90 days was Director William Shepard's purchase of 293 shares at $268.76 on September 25, worth roughly $79,000. Small in dollar terms, but it was a discretionary buy in the weeks heading into earnings. Net insider activity over 90 days is a small negative in aggregate, driven entirely by those withholding transactions. The largest institutional holders are passive: BlackRock at 8.5% of shares, Vanguard entities collectively around 9.7%, State Street at 4.5%. Capital Research added over 1.3 million shares in the most recently reported quarter, the largest single active-manager addition in the top-15.
The most recent comparable earnings event is worth noting directly. The July 22 Q2 print saw CME shares move 7.1% higher on the day and 11.8% higher over the subsequent five days. The short score has held in a narrow band around 31 for the past two weeks, suggesting no shift in ORTEX's composite view of short-side pressure. Peer exchange names were mixed this week: CBOE gained 5.1% while ICE added 1.9%, leaving CME's 2.9% weekly gain broadly in the middle of the pack.
With the Q3 print now one week away, the question sharpening is whether the volume and Market Data trends that drove the Q2 beat have held through the summer, and whether the FMX competitive narrative has moved from theoretical to measurable in the numbers.
See the live data behind this article on ORTEX.
Open CME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
